Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-05-10
2011-05-10
Cook, Lisa V (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007100, C436S501000, C436S518000, C422S050000, C530S300000, C530S350000
Reexamination Certificate
active
07939277
ABSTRACT:
The invention relates to a method for distinguishing between different states or forms of diseases and disorders characterized by thrombocytopenia and/or by spontaneous interaction between Von Willebrand Factor (vWF) and platelets, and/or to predict the progression of such a disease or disorder, said method comprising the steps of providing at least one biological sample obtained from a patient suffering from, or suspected to suffer from, at least one disease or disorder characterized by thrombocytopenia and/or by spontaneous interaction between Von Willebrand Factor (vWF) and platelets and of determining the amount of activated vWF in said biological sample, in which the amount of activated vWF in the sample is representative for the different states or forms of the disease or disorder. The invention further relates to a kit-of-parts for determining the amount of activated vWF in a sample and to the use of an antibody that is capable of specifically binding activated vWF in the presence of non-activated vWF; of a part or fragment of an antibody.
REFERENCES:
patent: 5238919 (1993-08-01), Zimmerman et al.
patent: 5670132 (1997-09-01), Griffiths et al.
patent: 5916805 (1999-06-01), Nagano et al.
patent: 5976532 (1999-11-01), Coller et al.
patent: 6228360 (2001-05-01), Co et al.
patent: 6251393 (2001-06-01), Handin et al.
patent: 6280731 (2001-08-01), Nagano et al.
patent: 6419934 (2002-07-01), Tobinick
patent: 6517829 (2003-02-01), Frenken et al.
patent: 6759518 (2004-07-01), Kontermann et al.
patent: 6793920 (2004-09-01), Nagano et al.
patent: 7311913 (2007-12-01), Co et al.
patent: 2001/0024647 (2001-09-01), McLeod et al.
patent: 2002/0028204 (2002-03-01), Kito et al.
patent: 2002/0058033 (2002-05-01), Raisch et al.
patent: 2003/0092892 (2003-05-01), Frenken et al.
patent: 2005/0136056 (2005-06-01), Kageyama et al.
patent: 2005/0192224 (2005-09-01), Huizinga et al.
patent: 2006/0149041 (2006-07-01), Silence
patent: 2006/0286066 (2006-12-01), Basran
patent: 2010/0022452 (2010-01-01), Silence et al.
patent: 0 295 645 (1988-12-01), None
patent: 0 368 684 (1994-03-01), None
patent: 0 952 218 (1999-10-01), None
patent: 1 002 861 (2000-05-01), None
patent: 03447005.4 (2003-01-01), None
patent: WO 90/10707 (1990-09-01), None
patent: WO 93/11161 (1993-06-01), None
patent: WO 94/04678 (1994-03-01), None
patent: WO 94/13806 (1994-06-01), None
patent: WO 94/25591 (1994-11-01), None
patent: WO 96/17078 (1996-06-01), None
patent: WO 97/38102 (1997-10-01), None
patent: WO 99/09055 (1999-02-01), None
patent: WO 99/23221 (1999-05-01), None
patent: WO 00/24781 (2000-05-01), None
patent: WO 01/02853 (2001-01-01), None
patent: WO 02/051351 (2002-07-01), None
patent: WO 02/057445 (2002-07-01), None
patent: PCT/EP03/06581 (2003-06-01), None
patent: PCT/EP03/07313 (2003-07-01), None
patent: PCT/BE03/00191 (2003-12-01), None
patent: PCT/BE03/00206 (2003-12-01), None
patent: WO 2004/003019 (2004-01-01), None
patent: WO 2004/015425 (2004-02-01), None
patent: WO 2004/041862 (2004-05-01), None
patent: WO 2004/041863 (2004-05-01), None
patent: WO 2004/041865 (2004-05-01), None
patent: WO 2004/041867 (2004-05-01), None
patent: WO 2005/044858 (2005-05-01), None
patent: WO 2006/074947 (2006-07-01), None
patent: WO 2006/122825 (2006-11-01), None
patent: WO 2008/049881 (2008-05-01), None
Murdock, Paul J, et al.,Thrombosis and Haemostasis, vol. 78, No. 4, 1997, pp. 1272-1277.
Paul Murdock et al. (Thromb. Haemost., vol. 78, pp. 1272-1277, 1997).
Favaloro, E.J. et al., “Discrimination of von Willebrand's Disease (VWD) subtypes: Direct comparison of von Willebrand factor: Collagen binding assay (VWF:CBA) with monoclonal antibody (MAB) based VWF-capture systems,”Thrombosis and HaemostasisOct. 2000; 84(4):541-547.
Favaloro, E.J. et al., “Detection of von Willebrand disorder and identification of qualitative von Willebrand factor defects: Direct comparison of commercial ELISA-based von Willebrand factor activity options,”American Journal of Clinical PathologyOct. 2000; 114(4):608-618.
Favaloro, E.J. et al., “Development of a simple collagen based ElLISA assay aids in the diagnosis of, and permits sensitive discrimination between Type I and Type II, von Willebrand's disease,”Blood Coagulation&Fibrinolysis1991; 2(2):285-291.
Lattuada, A. et al., “Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome,”HaematologicaSep. 2003; 88(9):1029-1034.
Murdock, P.J. et al., “Von Willebrand factor activity detected in a monoclonal antibody-based ELISA: An alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use,”Thrombosis and Haemostasis1997; 78(4):1272-1277.
Tsai, H.M. et al., “Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura,”New England Journal of MedicineNov. 26, 1998; 339(22):1585-1594.
Veyradier, A. et al., “Laboratory diagnosis of von Willebrand disease,”International Journal of Clinical&Laboratory Research1998; 28(4):201-210.
Vanhoorelbeke, K. et al., “A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factor,”Thrombosis and HaemostasisJan. 2000; 83(1):107-113.
[No Author Listed] The Merck Manual of Diagnosis and Therapy, 17thEd. Beers et al, Editors. Merck Research Laboratories, 1999:926-7.
[No Author Listed] Von Willebrand disease. www.wikipedia.org. Accessed Dec. 30, 2008.
Arbabi Gharoudi et al., Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett. Sep. 15, 1997;414(3):521-6.
Berndt et al., The vascular biology of the glycoprotein Ib-IX-V complex. Thromb Haemost. Jul. 2001;86(1):178-88. Review.
Blanco et al., Formation and stability of beta-hairpin structures in polypeptides. Curr Opin Struct Biol. Feb. 1998;8(1):107-11. Review.
Bonnefoy et al., Shielding the front-strand beta 3 of the von Willebrand factor A1 domain inhibits its binding to platelet glycoprotein Ibalpha. Blood. Feb. 15, 2003;101(4):1375-83. Epub Oct. 10, 2002.
Celikel et al., von Willebrand factor conformation and adhesive function is modulated by an internalized water molecule. Nat Struct Biol. Oct. 2000;7(10):881-4.
Celikel et al., Crystal structure of the von Willebrand factor A1 domain in complex with the function blocking NMC-4 Fab. Nat Struct Biol. Mar. 1998;5(3):189-94.
Chand et al., A two-site, monoclonal antibody-based immunoassay for von Willebrand factor—demonstration that vWF function resides in a conformational epitope. Thromb Haemost. Jun. 30, 1986;55(3):318-24.
Christophe et al., A monoclonal antibody (B724) to von Willebrand factor recognizing an epitope within the A1 disulphide loop (Cys509-Cys695) discriminates between type 2A and type 2B von Willebrand disease. Br J Haematol. May 1995;90(1):195-203.
Conrath et al., Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs. J Biol Chem. Mar. 9, 2001;276(10):7346-50. Epub Oct. 25, 2000.
Cortez-Retamozo et al., Efficient tumor targeting by single-domain antibody fragments of camels. Int J Cancer. Mar. 20, 2002;98(3):456-62.
Cruz et al., Mapping the glycoprotein Ib-binding site in the von willebrand factor A1 domain. J Biol Chem. Jun. 23, 2000;275(25):19098-105.
De Mast et al., Thrombocytopenia and release of activated von willebrand factor during early plasmodium falciparum malaria . J. Inf. Diseases 2007; 196: 622-628.
D'Haens et al., Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology. May 1999;116(5):1029-34.
Dong et al., Novel gain-of-function mutations of platelet glycoprotein Ibalpha by valine mutagenesis in the Cys209-Cys248 disulfide loop. Functional analysis under statis and dynamic conditions. J Biol Chem. Sep. 8, 2000;275(36):27663-70.
Dong et al., Tyrosine sulfation of glycoprotein I(b)alpha. Role of electrostatic interactions in von
de Groot Philip G.
Fijnheer Rob
Lenting Peter J.
Silence Karen
Ablynx N.V.
Cook Lisa V
UMC Utrecht Holding BV
Wolf Greenfield & Sacks P.C.
LandOfFree
Methods and assays for distinguishing between different... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and assays for distinguishing between different..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and assays for distinguishing between different... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2674654